

Erratum

In [1], the article accepted date was cited incorrectly. The correct article received and accepted dates should have read "Received: August 31, 2007; Accepted: October 1, 2007"

In [2], reference number 30 was omitted from the reference list, and so references 30–168, inclusive, were incorrect as cited in this article. The corrected reference list, from references 30–169 is given in the Appendix below.

We apologize for these errors.

References

1. **Mandache E, Popescu LM, Gherghiceanu M.** Myocardial interstitial Cajal-like cells (ICLC) and their nanostructural relationships with intercalated discs: shed vesicles as intermediates. *J Cell Mol Med.* 2007; 11: 1175–84.
2. **Stan RV.** Endothelial stomatal and fenestral diaphragms in normal vessels and angiogenesis. *J Cell Mol Med.* 2007; 11: 621–43.

Appendix: The following are corrected references 30–169 from article Stan RV. Endothelial stomatal and fenestral diaphragms in normal vessels and angiogenesis. *J Cell Mol Med.* 2007; 11: 621–43.

30. **Milici AJ, L'Hernault N, Palade GE.** Surface densities of diaphragmed fenestrae and transendothelial channels in different murine capillary beds. *Circ Res.* 1985; 56: 709–17.
31. **Roberts WG, Palade GE.** Endothelial fenestrae and fenestral diaphragms. In: Rissau W, Rubanyi GM, editors. Morphogenesis of endothelium. Amsterdam: Hardwood Academic Publishers; 2000. 23–41.
32. **Dvorak AM, Kohn S, Morgan ES, Fox P, Nagy JA, Dvorak HF.** The vesiculo-vacuolar organelle (VVO): a distinct endothelial cell structure that provides a transcellular pathway for macromolecular extravasation. *J Leukoc Biol.* 1996; 59: 100–15.
33. **Feng D, Nagy JA, Pyne K, Hammel I, Dvorak HF, Dvorak AM.** Pathways of macromolecular extravasation across microvascular endothelium in response to VPF/VEGF and other vasoactive mediators. *Microcirculation.* 1999; 6: 23–44.
34. **Feng D, Nagy JA, Dvorak HF, Dvorak AM.** Ultrastructural studies define soluble macromolecular, particulate, and cellular transendothelial cell pathways in venules, lymphatic vessels, and tumour-associated microvessels in man and animals. *Microsc Res Tech.* 2002; 57: 289–326.
35. **Kohn S, Nagy JA, Dvorak HF, Dvorak AM.** Pathways of macromolecular tracer transport across venules and small veins. Structural basis for the hyperpermeability of tumour blood vessels. *Lab Invest.* 1992; 67: 596–607.
36. **Vasile E, Dvorak AM, Stan RV, Dvorak HF.** Isolation and characterization of caveolae and vesiculo-vacuolar organelles from endothelial cells cultured with VPF/VEGF and from human lung. *Mol Biol Cell.* 2000; 11: 121.
37. **Zhao YY, Liu Y, Stan RV, Fan L, Gu Y, Dalton N, Chu PH, Peterson K, Ross J Jr, Chier KR.** Defects in caveolin-1 cause dilated cardiomyopathy and pulmonary hypertension in knockout mice. *Proc Natl Acad Sci USA.* 2002; 99: 11375–80.
38. **Stan RV.** Channels across endothelial cells. In: Baluska F, Volkmann D, Barlowe PW, editors. Cell-cell channels. Georgetown, TX: Landes Biosciences; 2006. 271–8.
39. **Yoshida Y, Yamada M, Wakabayashi K, Ikuta F.** Endothelial fenestrae in the rat fetal cerebrum. *Brain Res Dev Brain Res.* 1988; 44: 211–9.
40. **Milici AJ, Bankston PW.** Fetal and neonatal rat intestinal capillaries: a TEM study of changes in the mural structure. *Am J Anat.* 1981; 160: 435–48.
41. **Milici AJ, Bankston PW.** Fetal and neonatal rat intestinal capillaries: permeability to carbon, ferritin, hemoglobin, and myoglobin. *Am J Anat.* 1982; 165: 165–86.
42. **Naito M, Wisse E.** Observations on the fine structure and cytochemistry of sinusoidal cells in fetal and neonatal liver. In: Wisse E, editor. Kupffer cells and other liver sinusoidal cells. Amsterdam: Elsevier; 1977. pp. 497–505.

43. **Bankston PW, Pino RM.** The development of the sinusoids of fetal rat liver: morphology of endothelial cells, Kupffer cells, and the transmural migration of blood cells into the sinusoids. *Am J Anat.* 1980; 159: 1–15.
44. **Stan RV, Arden KC, Palade GE.** cDNA and protein sequence, genomic organization, and analysis of cis regulatory elements of mouse and human PLVAP genes. *Genomics.* 2001; 72: 304–13.
45. **Hallmann R, Mayer DN, Berg EL, Broermann R, Butcher EC.** Novel mouse endothelial cell surface marker is suppressed during differentiation of the blood brain barrier. *Dev Dyn.* 1995; 202: 325–32.
46. **Bradbury MW.** The structure and function of the blood-brain barrier. *Fed Proc.* 1984; 43: 186–90.
47. **Margulies EH, Kardia SL, Innis JW.** A comparative molecular analysis of developing mouse forelimbs and hindlimbs using serial analysis of gene expression (SAGE). *Genome Res.* 2001; 11: 1686–98.
48. **Penn PE, Jiang DZ, Fei RG, Sitnicka E, Wolf NS.** Dissecting the hematopoietic microenvironment. IX. Further characterization of murine bone marrow stromal cells. *Blood.* 1993; 81: 1205–13.
49. **Vittet D, Prandini MH, Berthier R, Schweitzer A, Martin-Sisteron H, Uzan G, Dejana E.** Embryonic stem cells differentiate *in vitro* to endothelial cells through successive maturation steps. *Blood.* 1996; 88: 3424–31.
50. **Helisch A, Schaper W.** Arteriogenesis: the development and growth of collateral arteries. *Microcirculation.* 2003; 10: 83–97.
51. **Scholz D, Ito W, Fleming I, Deindl E, Sauer A, Wiesnet M, Busse R, Schaper J, Schaper W.** Ultrastructure and molecular histology of rabbit hind-limb collateral artery growth (arteriogenesis). *Virchows Arch.* 2000; 436: 257–70.
52. **Wolf C, Cai WJ, Vosschulte R, Koltai S, Mousavipour D, Scholz D, Afsah-Hedjri A, Schaper W, Schaper J.** Vascular remodeling and altered protein expression during growth of coronary collateral arteries. *J Mol Cell Cardiol.* 1998; 30: 2291–305.
53. **McKinney RV, Jr., Singh BB, Brewer PD.** Fenestrations in regenerating skeletal muscle capillaries. *Am J Anat.* 1977; 150: 213–8.
54. **Oki S, Desaki J, Matsuda Y, Shibata T, Okumura H.** Capillaries with fenestrations around regenerating muscle fibers in the soleus muscle of the dystrophic (dy) mouse. *J Orthop Sci.* 1998; 3: 67–70.
55. **Desaki J, Oki S, Matsuda Y, Sakanaka M.** Morphological changes of capillaries in the rat soleus muscle following experimental tenotomy. *J Electron Microsc.* 2000; 49: 185–93.
56. **Ghatak NR, Nochlin D.** Fenestrated blood vessels in human skeletal muscle. *Acta Neuropathol.* 1979; 47: 169–74.
57. **Braverman IM, Yen A.** Ultrastructure of the capillary loops in the dermal papillae of psoriasis. *J Invest Dermatol.* 1977; 68: 53–60.
58. **de Almeida OP, Bohm GM.** Vascular permeability in the rat gingiva. A model of vessel response in chronic inflammation. *J Pathol.* 1979; 127: 27–34.
59. **Kawanami O, Matsuda K, Yoneyama H, Ferrans VJ, Crystal RG.** Endothelial fenestration of the alveolar capillaries in interstitial fibrotic lung diseases. *Acta Pathol Japan.* 1992; 42: 177–84.
60. **Snyder DH, Valsamis MP, Stone SH, Raine CS.** Progressive demyelination and reparative phenomena in chronic experimental allergic encephalomyelitis. *J Neuropathol Exp Neurol.* 1975; 34: 209–21.
61. **Llena JF, Cespedes G, Hirano A, Zimmerman HM, Feiring EH, Fine D.** Vascular alterations in delayed radiation necrosis of the brain. An electron microscopical study. *Arch Pathol Lab Med.* 1976; 100: 531–4.
62. **Hirano A, Kawanami T, Llena JF.** Electron microscopy of the blood-brain barrier in disease. *Microsc Res Tech.* 1994; 27: 543–56.
63. **Wallow IH, Geldner PS.** Endothelial fenestrae in proliferative diabetic retinopathy. *Invest Ophthalmol Vis Sci.* 1980; 19: 1176–83.
64. **Detmar M, Brown LF, Claffey KP, Yeo KT, Kocher O, Jackman RW, Berse B, Dvorak HF.** Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. *J Exp Med.* 1994; 180: 1141–6.
65. **Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF.** Tumour cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. *Science.* 1983; 219: 983–5.
66. **Pappas GD, Sagen J.** Fine structural correlates of vascular permeability of chromaffin cell transplants in CNS pain modulatory regions. *Exp Neurol.* 1988; 102: 280–9.
67. **Shibata S, Fukushima M, Mori K.** Ultrastructure of capillary permeability in human brain tumours. 2: Mechanisms of contrast enhancement in gliomas. *No Shinkei Geka.* 1986; 14: 311–6.
68. **Capo V, Ozzello L, Fenoglio CM, Lombardi L, Rilke F.** Angiosarcomas arising in edematous extremities: immunostaining for factor VIII-related antigen and ultrastructural features. *Hum Pathol.* 1985; 16: 144–50.
69. **Front D, Israel O, Kohn S, Nir I.** The blood-tissue barrier of human brain tumours: correlation of scintigraphic and ultrastructural findings: concise communication. *J Nucl Med.* 1984; 25: 461–5.
70. **Wagner RF, Jr., Gerard G, Sciubba JJ.** Amelanotic melanoma of the lung and brain with fenestrated intrinsic tumour capillaries. *Surg Neurol.* 1981; 15: 384–8.

71. **Ludatscher RM, Gellei B, Barzilai D.** Ultrastructural observations on the capillaries of human thyroid tumours. *J Pathol.* 1979; 128: 57–62.
72. **Kasantikul V, Glick AD, Netsky MG.** Light and electron microscopic observations of blood vessels in neurilemoma. *Arch Pathol Lab Med.* 1979; 103: 683–7.
73. **Wisse E, Braet F, Luo D, De Zanger R, Jans D, Crabbe E, Vermoesen A.** Structure and function of sinusoidal lining cells in the liver. *Toxicol Pathol.* 1996; 24: 100–11.
74. **Madigan MC, Penfold PL.** Human retinoblastoma: a morphological study of apoptotic, leukocytic, and vascular elements. *Ultrastruct Pathol.* 1997; 21: 95–107.
75. **Jin E, Fujiwara M, Nagashima M, Shimizu H, Ghazizadeh M, Pan X, Arai S, Ohaki Y, Gomibuchi M, Takemura T, Kawanami O.** Aerogenous spread of primary lung adenocarcinoma induces ultrastructural remodeling of the alveolar capillary endothelium. *Hum Pathol.* 2001; 32: 1050–8.
76. **Jin E, Ghazizadeh M, Fujiwara M, Nagashima M, Shaimizu H, Ohaki Y, Arai S, Gomibuchi M, Takerara T, Kawarami O.** Angiogenesis and phenotypic alteration of alveolar capillary endothelium in areas of neoplastic cell spread in primary lung adenocarcinoma. *Pathol Int.* 2001; 51: 691–700.
77. **Stan RV, Ghitescu L, Jacobson BS, Palade GE.** Isolation, cloning, and localization of rat PV-1, a novel endothelial caveolar protein. *J Cell Biol.* 1999; 145: 1189–98.
78. **Stan RV, Kubitz M, Palade GE.** PV-1 is a component of the fenestral and stomatal diaphragms in fenestrated endothelia. *Proc Natl Acad Sci USA.* 1999; 96: 13203–7.
79. **Ghitescu LD, Crine P, Jacobson BS.** Antibodies specific to the plasma membrane of rat lung microvascular endothelium. *Exp Cell Res.* 1997; 232: 47–55.
80. **Stan RV, Roberts WG, Predescu D, Ihida K, Saucan L, Ghitescu L, Palade GE.** Immunolocalization and partial characterization of endothelial plasmalemmal vesicles (caveolae). *Mol Biol Cell.* 1997; 8: 595–605.
81. **Hnasko R, McFarland M, Ben-Jonathan N.** Distribution and characterization of plasmalemma vesicle protein-1 in rat endocrine glands. *J Endocrinol.* 2002; 175: 649–61.
82. **Lupas A.** Prediction and analysis of coiled-coil structures. *Methods Enzymol.* 1996; 266: 513–25.
83. **Hnasko R, Ben-Jonathan N.** Developmental regulation of PV-1 in rat lung: association with the nuclear envelope and limited colocalization with Cav-1. *Am J Physiol Lung Cell Mol Physiol.* 2005; 288: L275–84.
84. **Hnasko R, Carter JM, Medina F, Frank PG, Lisanti MP.** PV-1 labels trans-cellular openings in mouse endothelial cells and is negatively regulated by VEGF. *Cell Cycle.* 2006; 5: 2021–8.
85. **Hnasko R, Frank PG, Ben-Jonathan N, Lisanti MP.** PV-1 is negatively regulated by VEGF in the lung of caveolin-1, but not caveolin-2, null mice. *Cell Cycle.* 2006; 5: 2012–20.
86. **Durr E, Yu J, Krasinska KM, Carver LA, Yates JR, Testa JE, Oh P, Schnitzer JE.** Direct proteomic mapping of the lung microvascular endothelial cell surface *in vivo* and in cell culture. *Nat Biotechnol.* 2004; 22: 985–92.
87. **Oh P, Li Y, Yu J, Durr E, Krasinska KM, Carver LA, Testa JE, Schnitzer JE.** Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy. *Nature.* 2004; 429: 629–35.
88. **Monfared A, Blevins NH, Cheung EL, Jung JC, Popelka G, Schnitzer MJ.** *In vivo* imaging of mammalian cochlear blood flow using fluorescence microendoscopy. *Otol Neurotol.* 2006; 27: 144–52.
89. **Valadon P, Garnett JD, Testa JE, Bauerle M, Oh P, Schnitzer JE.** Screening phage display libraries for organ-specific vascular immunotargeting *in vivo*. *Proc Natl Acad Sci USA.* 2006; 103: 407–12.
90. **Lampugnani MG, Orsenigo F, Gagliani MC, Tacchetti C, Dejana E.** Vascular endothelial cadherin controls VEGFR-2 internalization and signaling from intracellular compartments. *J Cell Biol.* 2006; 174: 593–604.
91. **Ioannidou S, Deinhardt K, Miotla J, Bradley J, Cheung E, Samuelsson S, Ng YS, Shina DT.** An *in vitro* assay reveals a role for the diaphragm protein PV-1 in endothelial fenestra morphogenesis. *Proc Natl Acad Sci USA.* 2006; 103: 16770–5.
92. **Stan RV, Tkachenko E, Niesman IR.** PV1 is a key structural component for the formation of the stomatal and fenestral diaphragms. *Mol Biol Cell.* 2004; 15: 3615–30.
93. **Stan RV.** Multiple PV1 dimers reside in the same stomatal or fenestral diaphragm. *Am J Physiol Heart Circ Physiol.* 2004; 286: H1347–53.
94. **Simionescu M, Simionescu N, Palade GE.** Differentiated microdomains on the luminal surface of capillary endothelium: distribution of lectin receptors. *J Cell Biol.* 1982; 94: 406–13.
95. **Pino RM.** The cell surface of a restrictive fenestrated endothelium. II. Dynamics of cationic ferritin binding and the identification of heparin and heparan sulfate domains on the choriocapillaris. *Cell Tissue Res.* 1986; 243: 157–64.
96. **Furuya S.** Ultrastructure and formation of diaphragmed fenestrae in cultured endothelial cells

- of bovine adrenal medulla. *Cell Tissue Res.* 1990; 261: 97–105.
97. **Bankston PW, Porter GA, Milici AJ, Palade GE.** Differential and specific labeling of epithelial and vascular endothelial cells of the rat lung by Lycopersicon esculentum and Griffonia simplicifolia I lectins. *Eur J Cell Biol.* 1991; 54: 187–95.
 98. **Bankston PW, Milici AJ.** A survey of the binding of polycationic ferritin in several fenestrated capillary beds: indication of heterogeneity in the luminal glyco-calyx of fenestral diaphragms. *Microvasc Res.* 1983; 26: 36–48.
 99. **Simionescu M, Simionescu N, Palade GE.** Preferential distribution of anionic sites on the base-ment membrane and the abluminal aspect of the endothelium in fenestrated capillaries. *J Cell Biol.* 1982; 95: 425–34.
 100. **Simionescu M, Simionescu N, Palade GE.** Partial chemical characterization of the anionic sites in the basal lamina of fenestrated capillaries. *Microvasc Res.* 1984; 28: 352–67.
 101. **Roberts WG, Palade GE.** Neovasculature induced by vascular endothelial growth factor is fenestrated. *Cancer Res.* 1997; 57: 765–72.
 102. **Palade GF, Simionescu M, Simionescu N.** Differentiated microdomains on the luminal surface of the capillary endothelium. *Biorheology.* 1981; 18: 563–8.
 103. **Rosenberg RD, Shworak NW, Liu J, Schwartz JJ, Zhang L.** Heparan sulfate proteoglycans of the cardiovascular system. Specific structures emerge but how is synthesis regulated? *J Clin Invest.* 1997; 99: 2062–70.
 104. **Esko JD, Lindahl U.** Molecular diversity of heparan sulfate. *J Clin Invest.* 2001; 108: 169–73.
 105. **Sorensson J, Fierlbeck W, Heider T, Schwarz K, Park DS, Mundel P, Lisanti M, Ballermann BJ.** Glomerular endothelial fenestrae *in vivo* are not formed from caveolae. *J Am Soc Nephrol.* 2002; 13: 2639–47.
 106. **Roberts WG, Palade GE.** Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. *J Cell Sci.* 1995; 108: 2369–79.
 107. **Roberts WG, Delaat J, Nagane M, Huang S, Cavenee WK, Palade GE.** Host microvasculature influence on tumour vascular morphology and endothelial gene expression. *Am J Pathol.* 1998; 153: 1239–48.
 108. **Rhodin JA.** The diaphragm of capillary endothelial fenestrations. *J Ultrastruct Res.* 1962; 6: 171–85.
 109. **Schnitzer JE, Shen CP, Palade GE.** Lectin analysis of common glycoproteins detected on the surface of continuous microvascular endothelium *in situ* and in culture: identification of sialoglycoproteins. *Eur J Cell Biol.* 1990; 52: 241–51.
 110. **Stolz DB, Jacobson BS.** Macro- and microvascular endothelial cells *in vitro*: maintenance of biochemical heterogeneity despite loss of ultrastructural characteristics. *in vitro Cell Dev Biol.* 1991; 27A: 169–82.
 111. **Folkman J, Haudenschild C.** Angiogenesis *in vitro*. *Nature.* 1980; 288: 551–6.
 112. **Lombardi T, Montesano R, Furie MB, Silverstein SC, Orci L.** Endothelial diaphragmed fenestrae: in vitro modulation by phorbol myristate acetate. *J Cell Biol.* 1986; 102: 1965–70.
 113. **Madden SL, Cook BP, Nacht M, Weber WD, Callahan MR, Jiang Y, Dufault MR, Zhang X, Zhang W, Walter-Yohrling J, Rouleau C, Akmaev VR, Wang CJ, Cao X, St Martin TB, Roberts BL, Teicher BA, Klinger KW, Stan RV, Lucey B, Carson-Walter EB, Latterra J, Walter KA.** Vascular gene expression in nonneoplastic and malignant brain. *Am J Pathol.* 2004; 165: 601–8.
 114. **Vasile E, Qu H, Dvorak HF, Dvorak AM.** Caveolae and vesiculo-vacuolar organelles in bovine capillary endothelial cells cultured with VPF/VEGF on floating matrigel-collagen gels. *J Histochem Cytochem.* 1999; 47: 159–67.
 115. **Bendayan M.** Pathway of insulin in pancreatic tissue on its release by the B-cell. *Am J Physiol.* 1993; 264: G187–94.
 116. **Lombardi T, Montesano R, Furie MB, Silverstein SC, Orci L.** *In vitro* modulation of endothelial fenestrae: opposing effects of retinoic acid and transform-ing growth factor beta. *J Cell Sci.* 1988; 91: 313–8.
 117. **Lombardi T, Montesano R, Orci L.** Phorbol ester induces diaphragmed fenestrae in large vessel endothelium *in vitro*. *Eur J Cell Biol.* 1987; 44: 86–9.
 118. **Koya M, Chang L, Truong A, Brightman MW.** Chemical induction of fenestrae in vessels of the blood-brain barrier. *Exp Neurol.* 1996; 142: 6–13.
 119. **Kazanietz MG.** Novel “nonkinase” phorbol ester receptors: the C1 domain connection. *Mol Pharmacol.* 2002; 61: 759–67.
 120. **Breier G, Albrecht U, Sterrer S, Risau W.** Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation. *Development.* 1992; 114: 521–32.
 121. **Connolly DT, Olander JV, Heuvelman D, Nelson R, Monsell R, Siegel N, Haymore BL.** Human vascular permeability factor. Isolation from U937 cells. *J Biol Chem.* 1989; 264: 20017–24.
 122. **Esser S, Wolburg K, Wolburg H, Breier G, Kurzchalia T, Risau W.** Vascular endothelial growth factor induces endothelial fenestrations *in vitro*. *J Cell Biol.* 1998; 140: 947–59.

123. **Böttinger EP, Letterio JJ, Roberts AB.** Biology of TGF-beta in knockout and transgenic mouse models. *Kidney Int.* 1997; 51: 1355–60.
124. **Grunstein J, Roberts WG, Mathieu-Costello O, Hanahan D, Johnson RS.** Tumour-derived expression of vascular endothelial growth factor is a critical factor in tumour expansion and vascular function. *Cancer Res.* 1999; 59: 1592–8.
125. **Post MJ, Laham R, Sellke FW, Simons M.** Therapeutic angiogenesis in cardiology using protein formulations. *Cardiovasc Res.* 2001; 49: 522–31.
126. **Wadia JS, Dowdy SF.** Protein transduction technology. *Curr Opin Biotechnol.* 2002; 13: 52–6.
127. **Bates DO, Hillman NJ, Williams B, Neal CR, Pockock TM.** Regulation of microvascular permeability by vascular endothelial growth factors. *J Anat.* 2002; 200: 581–97.
128. **Etienne-Manneville S, Hall A.** Rho GTPases in cell biology. *Nature.* 2002 12; 420: 629–35.
129. **Chen J, Braet F, Brodsky S, Weinstein T, Romanov V, Noiri E, Goligorsky MS.** VEGF-induced mobilization of caveolae and increase in permeability of endothelial cells. *Am J Physiol Cell Physiol.* 2002; 282: C1053-63.
130. **Gerber HP, Hillan KJ, Ryan AM.** VEGF is required for growth and survival in neonatal mice. *Development.* 1999; 126: 1149–59.
131. **Lammert E, Gu G, McLaughlin M, Brown D, Brekken R, Murtaugh LC, Gerber HP, Ferrara N, Melton DA.** Role of VEGF-A in vascularization of pancreatic islets. *Curr Biol.* 2003; 13: 1070–4.
132. **Eremina V, Cui S, Gerber H.** Vascular endothelial growth factor a signaling in the podocyte-endothelial compartment is required for mesangial cell migration and survival. *J Am Soc Nephrol.* 2006; 17: 724–35.
133. **Mancuso MR, Davis R, Norberg SM, O'Brien S, Sennino B, Nakahara T, Yao VJ, Inai T, Brooks P, Freimark B, Shalinsky DR, Hu-Lowe DD, McDonald DM.** Rapid vascular regrowth in tumours after reversal of VEGF inhibition. *J Clin Invest.* 2006; 116: 2610–21.
134. **Kamba T, Tam BY, Hashizume H, Haskell A, Sennino B, Mancuso MR, Norberg, SM, O'Brien SM, Davis RB, Gouen LC, Anderson KO, Thurston G, Joho S, Spinger ML, Kuo CJ, McDonald DM.** VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. *Am J Physiol Heart Circ Physiol.* 2006; 290: H560–76.
135. **Baffert F, Le T, Sennino B, Thurston G, Kuo CJ, Hu-Lowe D, McDonald DM.** Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling. *Am J Physiol Heart Circ Physiol.* 2006; 290: H547–59.
136. **Inai T, Mancuso M, Hashizume H, Baffert F, Haskell A, Baluk P, Hu-Lowe DD, Shalinsky OR, Thurston G, Yancopoulos GD, McDonald DM.** Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumour vessels, and appearance of basement membrane ghosts. *Am J Pathol.* 2004; 165: 35–52.
137. **Baluk P, Lee CG, Link H, Ator E, Haskell A, Elias JA, McDonald DM.** Regulated angiogenesis and vascular regression in mice overexpressing vascular endothelial growth factor in airways. *Am J Pathol.* 2004; 165: 1071–85.
138. **Strickland LA, Jubb AM, Hongo JA, Zhong F, Burwick J, Fu L, Frantz GD, Koepfen H.** Plasmalemmal vesicle-associated protein (PLVAP) is expressed by tumour endothelium and is upregulated by vascular endothelial growth factor-A (VEGF). *J Pathol.* 2005; 206: 466–75.
139. **Carson-Walter EB, Hampton J, Shue E, Geynisman DM, Pillai PK, Sathanoori R, Madden SL, Hamilton RL, Walter KA.** Plasmalemmal vesicle associated protein-1 is a novel marker implicated in brain tumour angiogenesis. *Clin Cancer Res.* 2005; 11: 7643–50.
140. **Sanders Strickland LA, Koepfen H.** Comments on plasmalemmal vesicle associated protein-1 as a novel marker implicated in brain tumour angiogenesis. *Clin Cancer Res.* 2006; 12: 2649–50.
141. **Niemela H, Elima K, Henttinen T, Irjala H, Salmi M, Jalkanen S.** Molecular identification of PAL-E, a widely used endothelial-cell marker. *Blood.* 2005; 106: 3405–9.
142. **Schlingemann RO, Dingjan GM, Emeis JJ, Blok J, Warnaar SO, Ruiter DJ.** Monoclonal antibody PAL-E specific for endothelium. *Lab Invest.* 1985; 52: 71–6.
143. **Sundberg C, Ljungstrom M, Lindmark G, Gerdin B, Rubin K.** Microvascular pericytes express platelet-derived growth factor-beta receptors in human healing wounds and colorectal adenocarcinoma. *Am J Pathol.* 1993; 143: 1377–88.
144. **Paavonen K, Puolakkainen P, Jussila L, Jahkola T, Alitalo K.** Vascular endothelial growth factor receptor-3 in lymphangiogenesis in wound healing. *Am J Pathol.* 2000; 156: 1499–504.
145. **Schlingemann RO, Rietveld FJ, Kwaspfen F, van de Kerkhof PC, de Waal RM, Ruiter DJ.** Differential expression of markers for endothelial cells, pericytes, and basal lamina in the microvasculature of tumours and granulation tissue. *Am J Pathol.* 1991; 138: 1335–47.
146. **Ruiter DJ, Schlingemann RO, Westphal JR, Denijn M, Rietveld FJ, De Waal RM.** Angiogenesis in wound healing and tumour metastasis. *Behring Inst Mitt.* 1993; 92: 258–72.
147. **Witmer AN, van Blijswijk BC, van Noorden CJ, Vrensen GF, Schlingemann RO.** *In vivo* angiogenic phenotype of endothelial cells and pericytes induced

- by vascular endothelial growth factor-A. *J Histochem Cytochem.* 2004; 52: 39–52.
148. **Holden CA, Spaul J, Das AK, McKee PH, Jones EW.** The histogenesis of angiosarcoma of the face and scalp: an immunohistochemical and ultrastructural study. *Histopathology.* 1987; 11: 37–51.
 149. **Kahn HJ, Bailey D, Marks A.** Monoclonal antibody D2-40, a new marker of lymphatic endothelium, reacts with Kaposi's sarcoma and a subset of angiosarcomas. *Mod Pathol.* 2002; 15: 434–40.
 150. **Nadimi H, Saatee S, Armin A, Toto PD.** Expression of endothelial cell markers PAL-E and EN-4 and Ia-antigens in Kaposi's sarcoma. *J Oral Pathol.* 1988; 17: 416–20.
 151. **Schulze HJ, Rutten A, Mahrle G, Steigleder GK.** Initial lesions of HIV-related Kaposi's sarcoma—a histological, immunohistochemical, and ultrastructural study. *Arch Dermatol Res.* 1987; 279: 499–503.
 152. **Weninger W, Partanen TA, Breiteneder-Geleff S, Mager C, Kawalski H, Mildner M, Pammer J, Sturzl M, Kerjaschki D, Alitalo K, Tschachler E.** Expression of vascular endothelial growth factor receptor-3 and podoplanin suggests a lymphatic endothelial cell origin of Kaposi's sarcoma tumour cells. *Lab Invest.* 1999; 79: 243–51.
 153. **Sarawar SR, Schlingemann RO, Kelsey A, Fleming S, Kumar S.** A monoclonal antibody stains blastemal but not tubular components of Wilms' tumour. *J Pathol.* 1988; 156: 319–24.
 154. **Leenstra S, Das PK, Troost D, Bosch DA, Claessen N, Becker AE.** PAL-E, monoclonal antibody with immunoreactivity for endothelium specific to brain tumours. *Lancet.* 1990; 335: 671.
 155. **Leenstra S, Troost D, Das PK, Claessen N, Becker AE, Bosch DA.** Endothelial cell marker PAL-E reactivity in brain tumour, developing brain, and brain disease. *Cancer.* 1993; 72: 3061–7.
 156. **Renard N, Nooijen PT, Schalkwijk L, De Waal RM, Eggermont AM, Lienard D, Kroon BB, Lejeune FJ, Ruiter DJ.** VWF release and platelet aggregation in human melanoma after perfusion with TNF alpha. *J Pathol.* 1995; 176: 279–87.
 157. **Clarijs R, Schalkwijk L, Hofmann UB, Ruiter DJ, de Waal RM.** Induction of vascular endothelial growth factor receptor-3 expression on tumour microvasculature as a new progression marker in human cutaneous melanoma. *Cancer Res.* 2002; 62: 7059–65.
 158. **Nakamura S, Muro H, Suzuki S, Sakaguchi T, Konno H, Baba S, Syed AS.** Immunohistochemical studies on endothelial cell phenotype in hepatocellular carcinoma. *Hepatology.* 1997; 26: 407–15.
 159. **Nielsen BS, Sehested M, Kjeldsen L, Borregaard N, Rygaard J, Dano K.** Expression of matrix metalloprotease-9 in vascular pericytes in human breast cancer. *Lab Invest.* 1997; 77: 345–55.
 160. **Sauter B, Foedinger D, Sterniczky B, Wolff K, Rappersberger K.** Immunoelectron microscopic characterization of human dermal lymphatic microvascular endothelial cells. Differential expression of CD31, CD34, and type IV collagen with lymphatic endothelial cells vs blood capillary endothelial cells in normal human skin, lymphangioma, and hemangioma *in situ.* *J Histochem Cytochem.* 1998; 46: 165–76.
 161. **Feng D, Nagy JA, Brekken RA, Pettersson A, Manseau EJ, Pyne K, Mulligan R, Thorpe PE, Dvorak HF, Dvorak AM.** Ultrastructural localization of the vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) receptor-2 (FLK-1, KDR) in normal mouse kidney and in the hyperpermeable vessels induced by VPF/VEGF-expressing tumours and adenoviral vectors. *J Histochem Cytochem.* 2000; 48: 545–56.
 162. **Hofman P, Blaauwgeers HG, Tolentino MJ, Adamis AP, Nunes Cardozo BJ, Wensen GF, Schlingemann RO.** VEGF-A induced hyperpermeability of blood-retinal barrier endothelium *in vivo* is predominantly associated with pinocytotic vesicular transport and not with formation of fenestrations. Vascular endothelial growth factor-A. *Curr Eye Res.* 2000; 21: 637–45.
 163. **Cao R, Brakenhielm E, Wahlestedt C, Thyberg J, Cao Y.** Leptin induces vascular permeability and synergistically stimulates angiogenesis with FGF-2 and VEGF. *Proc Natl Acad Sci USA.* 2001; 98: 6390–5.
 164. **Goto J, Suganuma N, Takata K, Kitamura K, Asahina T, Kobayashi H, Muranaka Y, Furuhashi M, Kanayama N.** Morphological analyses of interleukin-8 effects on rat ovarian follicles at ovulation and luteinization *in vivo.* *Cytokine.* 2002; 20: 168–73.
 165. **Stan RV.** Endothelial diaphragms: nanogates of vascular permeability. *Anat Rec.* 2007; in press.
 166. **Stan RV.** Endothelial structures involved in vascular permeability. In press ed. Cambridge: Cambridge University Press; 2007.
 167. **Chang YS, di Tomaso E, McDonald DM, Jones R, Jain RK, Munn LL.** Mosaic blood vessels in tumours: frequency of cancer cells in contact with flowing blood. *Proc Natl Acad Sci USA.* 2000; 97: 14608–13.
 168. **Hashizume H, Baluk P, Morikawa S, McLean JW, Thurston G, Roberge S, Jain RK, McDonald DM.** Openings between defective endothelial cells explain tumour vessel leakiness. *Am J Pathol.* 2000; 156: 1363–80.
 169. **McDonald DM, Munn L, Jain RK.** Vasculogenic mimicry: how convincing, how novel, and how significant? *Am J Pathol.* 2000; 156: 383–8.